The dysregulation of intracellular calcium in Alzheimer disease

Topic: Amyloid, tau and blood-test diagnosis

Alzheimer disease (AD) is the most common neurodegenerative disorder worldwide and is at present, incurable. The accumulation of toxic amyloid-beta (Abeta) peptide aggregates in AD brain are thought to trigger the extensive synaptic loss and neurodegeneration linked to cognitive decline, an idea that underlies the 'amyloid hypothesis' of AD etiology in both the familal (FAD) and sporadic forms of the disease. Mutations causing FAD also result in the dysregulation of neuronal calcium (Ca2+) handling and may contribute to AD pathogenesis, an idea termed the 'calcium hypothesis' of AD. In particular, Ca2+ dysregulation by the endoplasmic reticulum (ER) in AD mouse models results in augmented cytosolic Ca2+ levels which can trigger signalling cascades that are detrimental to neuronal function and health. However, there is growing evidence to suggest that not all forms of Ca2+ dysregulation in AD neurons are harmful and some of them instead may be compensatory. These changes may help modulate neuronal excitability and slow AD pathology, especially in the early stages of the disease. Clearly, a better understanding of how dysregulation of neuronal Ca2+ handling contributes to neurodegeneration and neuroprotection in AD is needed as Ca2+ signalling modulators are targets of great interest as potential AD therapeutics.

Key findings

• Mutations causing FAD also result in the dysregulation of neuronal calcium (Ca2+) handling and may contribute to AD pathogenesis, an idea termed the 'calcium hypothesis' of AD.
• In particular, Ca2+ dysregulation by the endoplasmic reticulum (ER) in AD mouse models results in augmented cytosolic Ca2+ levels which can trigger signalling cascades that are detrimental to neuronal function and health.
• However, there is growing evidence to suggest that not all forms of Ca2+ dysregulation in AD neurons are harmful and some of them instead may be compensatory.

Study details

• Evidence strengthLow

Read the original

• DOI: 10.1016/j.ceca.2009.12.014
• PubMed: 20080301
• Original source →

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

@article{supnet2010-20080301,
  author  = {Supnet, C. and Bezprozvanny, I.},
  title   = {{The dysregulation of intracellular calcium in Alzheimer disease}},
  journal = {Cell calcium},
  year    = {2010},
  doi     = {10.1016/j.ceca.2009.12.014},
  pmid    = {20080301},
  url     = {https://doi.org/10.1016/j.ceca.2009.12.014}
}

Related studies in Disease mechanisms

• Calcium dysregulation contributes to neurodegeneration in FTLD patient iPSC-derived neurons Scientific reports · 2016-10-10 · usefulness score 40/100
• Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo Proceedings of the National Academy of Sciences · 2003-03-12 · usefulness score 56/100
• CaMKIIβ knockdown decreases store-operated calcium entry in hippocampal dendritic spines IBRO neuroscience reports · 2022-01-10 · usefulness score 41/100
• Calcium flux-independent NMDA receptor activity is required for Aβ oligomer-induced synaptic loss Cell death & disease · 2015-06-18 · usefulness score 40/100
• Urolithin A suppresses high glucose-induced neuronal amyloidogenesis by modulating TGM2-dependent ER-mitochondria contacts and calcium homeostasis Cell death and differentiation · 2020-07-23 · usefulness score 40/100
• The role of neuronal calcium sensors in balancing synaptic plasticity and synaptic dysfunction Frontiers in molecular neuroscience · 2012-05-04 · usefulness score 38/100

Also in Disease mechanisms

128 studies in the library are filed under Disease mechanisms with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Disease mechanisms hub.

• Disruption of blood-brain barrier in Alzheimer disease pathogenesis Tissue barriers · 2013-04-01 · usefulness score 40/100 · Disease mechanisms
• Alzheimer's Disease: Genes, Proteins, and Therapy Physiological Reviews · 2001-04-01 · usefulness score 58/100 · Disease mechanisms
• Alzheimer's disease-associated neurotoxic mechanisms and neuroprotective strategies Current drug targets. CNS and neurological disorders · 2005-08-01 · usefulness score 36/100 · Disease mechanisms

Similar studies

• Intracellular APP processing and A beta production in Alzheimer disease 1999 · Risk genes beyond APOE
• The keystone of Alzheimer pathogenesis might be sought in Aβ physiology 2015 · Disease mechanisms
• The Exceptional Vulnerability of Humans to Alzheimer's Disease 2017 · Disease mechanisms
• Alzheimer's disease, dementia, and stem cell therapy 2017 · Disease mechanisms
• New therapeutic targets in the neurovascular pathway in Alzheimer's disease 2008 · Disease mechanisms
• Alzheimer's disease 2013 · Disease mechanisms

More on Disease mechanisms

• A review that covers this ground Microbiota-Gut-Brain Axis Dysregulation in Alzheimer's Disease: Multi-Pathway Effects and Therapeutic Potential Aging and disease · 2024-05-07 · usefulness score 43/100
• Newest in this subject Aβ42 oligomers disrupt calcium homeostasis via Piezo1 and induce neurotoxicity in differentiated SH-SY5Y cells Research Square · 2026-10-29 · Preprint — not yet peer-reviewed · usefulness score 16/100
• Newest in this subject Neuronal Hyperactivity Induces Tau Phosphorylation Selectively in Excitatory Pyramidal Neurons Which Contributes to GluA2 Regulation bioRxiv · 2026-10-28 · Preprint — not yet peer-reviewed · usefulness score 16/100

See all studies in Disease mechanisms →